Avyxa Holdings Drug Patent Portfolio
Avyxa Holdings owns 2 orange book drugs protected by 3 US patents Given below is the list of Avyxa Holdings's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10398785 | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use | 14 Mar, 2036 | Active |
| US11382923 | Stable liquid formulations of cyclophosphamide and processes to prepare the same | 01 Dec, 2035 | Active |
| US10849916 | Stable liquid formulations of cyclophosphamide and its impurities | 13 Jul, 2035 | Active |
Latest Legal Activities on Avyxa Holdings's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Avyxa Holdings.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 May, 2024 | US10849916 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 May, 2024 | US10993952 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Sep, 2022 | US10398785 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Jul, 2022 | US11382923 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Jul, 2022 | US11382923 |
|
Email Notification
Critical
| 23 Jun, 2022 | US11382923 |
|
Issue Notification Mailed
Critical
| 22 Jun, 2022 | US11382923 |
| Dispatch to FDC | 08 Jun, 2022 | US11382923 |
|
Application Is Considered Ready for Issue
Critical
| 08 Jun, 2022 | US11382923 |
|
Issue Fee Payment Received
Critical
| 06 Jun, 2022 | US11382923 |
|
Issue Fee Payment Verified
Critical
| 06 Jun, 2022 | US11382923 |
| Letter Accepting Correction of Inventorship Under Rule 1.48 | 06 May, 2022 | US11382923 |
|
Email Notification
Critical
| 06 May, 2022 | US11382923 |
| Filing Receipt - Updated | 06 May, 2022 | US11382923 |
| Miscellaneous Incoming Letter | 03 May, 2022 | US11382923 |
Avyxa Holdings's Family Patents
Avyxa Holdings Drug List
Given below is the complete list of Avyxa Holdings's drugs and the patents protecting them.
1. Cyclophosphamide
Cyclophosphamide is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11382923 | Stable liquid formulations of cyclophosphamide and processes to prepare the same |
01 Dec, 2035
(11 years from now)
| Active |
| US10849916 | Stable liquid formulations of cyclophosphamide and its impurities |
13 Jul, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cyclophosphamide's drug page
2. Docivyx
Docivyx is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10398785 | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use |
14 Mar, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Docivyx's drug page